US FDA grants fast track status to LISCure’s LB-P8 drug for PSC

2024-04-01

快速通道孤儿药临床1期临床2期临床申请

US FDA grants fast track status to LISCure’s LB-P8 drug for PSC

Preview

来源: Pharmaceutical Technology

LISCure expects Phase II study preliminary results in early 2025. Credit: BlurryMe/Shutterstock.com.

The US Food and Drug Administration (FDA) has granted fast track designation to LISCure Biosciences’ investigational drug LB-P8, for the treatment of primary sclerosing cholangitis (PSC).

With the designation, the company will fast track the development of the drug to fulfill the unmet medical needs of people affected by PSC.

LB-P8 is designed to treat inflammation and fibrosis as well as to modulate bile acids.

LISCure said the LB-P8 live biotherapeutic product (LBP) is the only one of its kind reported to be in clinical development for PSC, a rare and chronic liver disease with no approved treatment options.

The drug previously received orphan drug designation for PSC in 2022.

See Also:

Morris & Dickson will distribute mpox vaccine Jynneos in the US

Preview

来源: Pharmaceutical Technology

FDA accepts AstraZeneca-Daiichi Sankyo’s Datopotamab deruxtecan BLA

Preview

来源: Pharmaceutical Technology

Its safety and key biomarkers have been confirmed in a Phase I study.

LISCure plans to conduct a Phase II study across multiple sites in the US and Europe, with preliminary results expected in early 2025.

It is also under development for metabolic dysfunction-associated steatohepatitis (MASH).

LISCure clinical development head Jiyoung Ahn said: “Receiving fast track designation is a significant milestone in addressing the high unmet medical need for PSC, and it will facilitate the efficient development of LB-P8 by enabling close communication with the regulatory authority.

“By having enhanced communication with the regulatory authority, we will expeditiously bring forward a novel therapy option in an area with limited available treatments.”